New antibiotics for Gram-negative pneumonia.
Bassetti M, Magnè F, Giacobbe DR, Bini L, Vena A.
Eur Respir Rev. 2022 Dec 21;31(166):220119. doi: 10.1183/16000617.0119-2022. Print 2022 Dec 31.
Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia.
Cillóniz C, Dominedò C, Torres A.
Crit Care. 2019 Mar 9;23(1):79. doi: 10.1186/s13054-019-2371-3.
Hospital-acquired infections due to gram-negative bacteria.
Peleg AY, Hooper DC.
N Engl J Med. 2010 May 13;362(19):1804-13. doi: 10.1056/NEJMra0904124.
An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria.
Cillóniz C, Dominedò C, Torres A.
Curr Opin Infect Dis. 2019 Dec;32(6):656-662. doi: 10.1097/QCO.0000000000000596.
Pneumonia mortality, comorbidities matter?
Hespanhol V, Bárbara C.
Pulmonology. 2020 May-Jun;26(3):123-129. doi: 10.1016/j.pulmoe.2019.10.003. Epub 2019 Nov 29.
Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria.
Watkins RR, Van Duin D.
F1000Res. 2019 Jan 30;8:F1000 Faculty Rev-121. doi: 10.12688/f1000research.16517.2. eCollection 2019.
Management of ventilator-associated pneumonia (VAP) caused by resistant gram-negative bacteria: which is the best strategy to treat?
Sarda C, Fazal F, Rello J.
Expert Rev Respir Med. 2019 Aug;13(8):787-798. doi: 10.1080/17476348.2019.1632195. Epub 2019 Jun 24.
The role of gram-negative bacteria in healthcare-associated pneumonia.
Restrepo MI, Anzueto A.
Semin Respir Crit Care Med. 2009 Feb;30(1):61-6. doi: 10.1055/s-0028-1119810. Epub 2009 Feb 6.
Risk factors of carbapenem-resistant gram-negative bacteria pneumonia and mortality.
Wenwen S, Xiquan L, Aiqin L.
Cell Mol Biol (Noisy-le-grand). 2022 Sep 30;68(10):124-129. doi: 10.14715/cmb/2022.68.10.20.
New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia: USA vs. Europe.
Martin-Loeches I, Rodriguez AH, Torres A.
Curr Opin Crit Care. 2018 Oct;24(5):347-352. doi: 10.1097/MCC.0000000000000535.
